ATE236406T1 - Verfahren zur prognose von prostata krebs - Google Patents

Verfahren zur prognose von prostata krebs

Info

Publication number
ATE236406T1
ATE236406T1 AT97931170T AT97931170T ATE236406T1 AT E236406 T1 ATE236406 T1 AT E236406T1 AT 97931170 T AT97931170 T AT 97931170T AT 97931170 T AT97931170 T AT 97931170T AT E236406 T1 ATE236406 T1 AT E236406T1
Authority
AT
Austria
Prior art keywords
thymosin beta
gene
cancers
seq
members
Prior art date
Application number
AT97931170T
Other languages
English (en)
Inventor
Bruce R Zetter
Lere Bao
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE236406T1 publication Critical patent/ATE236406T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5759—Thymosin or related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Steroid Compounds (AREA)
AT97931170T 1996-06-17 1997-06-13 Verfahren zur prognose von prostata krebs ATE236406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/664,857 US5858681A (en) 1996-06-17 1996-06-17 Method for prognosis of prostate cancer
PCT/US1997/010306 WO1997048982A1 (en) 1996-06-17 1997-06-13 A method for diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
ATE236406T1 true ATE236406T1 (de) 2003-04-15

Family

ID=24667736

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97931170T ATE236406T1 (de) 1996-06-17 1997-06-13 Verfahren zur prognose von prostata krebs
AT02020049T ATE314652T1 (de) 1996-06-17 1997-06-13 Verfahren zur diagnose von prostatakrebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02020049T ATE314652T1 (de) 1996-06-17 1997-06-13 Verfahren zur diagnose von prostatakrebs

Country Status (11)

Country Link
US (2) US5858681A (de)
EP (2) EP0922223B1 (de)
JP (1) JP3642431B2 (de)
AT (2) ATE236406T1 (de)
AU (1) AU723144B2 (de)
CA (1) CA2257858A1 (de)
DE (2) DE69720471T2 (de)
DK (1) DK0922223T3 (de)
ES (1) ES2196345T3 (de)
PT (1) PT922223E (de)
WO (1) WO1997048982A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2379264A1 (en) 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
US20020155514A1 (en) * 2000-12-01 2002-10-24 Hale Laura P. Zinc alpha-2-glycoprotein as indicator of cancer
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GR1004636B (el) * 2001-11-28 2004-07-14 ����������������������������������������}�����B�@�@����������@�� Προγνωσηατουακαρκινουαμεαχρησηατησαθυμοσινησαβ@α}τβ@bαα
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
CA2496236A1 (en) * 2002-08-21 2004-03-04 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US20060105343A1 (en) * 2003-01-09 2006-05-18 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
EP2674435A3 (de) 2006-03-24 2014-04-30 Phenomenome Discoveries Inc. Biomarker zur Diagnose von Prostatakrebs und Verfahren dafür
US7449715B2 (en) * 2006-04-06 2008-11-11 Xerox Corporation Poly[bis(ethynyl)heteroacene]s and electronic devices generated therefrom
JP5470848B2 (ja) 2006-08-04 2014-04-16 味の素株式会社 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置
WO2008075662A1 (ja) 2006-12-21 2008-06-26 Ajinomoto Co., Inc. 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体
EP2096439A4 (de) 2006-12-21 2011-01-05 Ajinomoto Kk Verfahren zur beurteilung von kolorektalkarzinom, kolorektalkarzinom-beurteilungsvorrichtung, -verfahren, -system, -programm und aufzeichnungsmedium
WO2009154297A1 (ja) 2008-06-20 2009-12-23 味の素株式会社 前立腺疾患の評価方法
GB2476789A (en) 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248591A (en) * 1991-05-02 1993-09-28 Puente Fernando D Diagnosis of cancer and other proliferative disorders by analysis of prothymosin alpha expression

Also Published As

Publication number Publication date
DE69735020T2 (de) 2006-07-27
EP0922223B1 (de) 2003-04-02
ES2196345T3 (es) 2003-12-16
DE69720471D1 (de) 2003-05-08
AU3487497A (en) 1998-01-07
PT922223E (pt) 2003-08-29
EP0922223A1 (de) 1999-06-16
AU723144B2 (en) 2000-08-17
EP1270745A2 (de) 2003-01-02
DE69720471T2 (de) 2004-02-19
WO1997048982A1 (en) 1997-12-24
ATE314652T1 (de) 2006-01-15
US6150117A (en) 2000-11-21
CA2257858A1 (en) 1997-12-24
DK0922223T3 (da) 2003-07-14
DE69735020D1 (de) 2006-02-02
JP2000513098A (ja) 2000-10-03
JP3642431B2 (ja) 2005-04-27
US5858681A (en) 1999-01-12
EP1270745B1 (de) 2005-12-28
EP1270745A3 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
DE69720471D1 (de) Verfahren zur prognose von prostata krebs
US7858325B2 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP0284362A2 (de) Molekulare Markierungen
CA2328989A1 (en) Serpentine transmembrane antigens expressed in human cancers and uses thereof
Glynne‐Jones et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence
Kaname et al. The expression of truncated MK in human tumors
ATE318314T1 (de) Verfahren zur bestimmung des metastasierungspotentials unter verwendung des asp1 gens
IL186154A0 (en) Methods and compositions for inhibiting neoplastic cell growth
DK1032668T3 (da) Fibroblast vækstfaktor 19
ATE364628T1 (de) Verfahren und zusammensetzungen zur diagnose von tumoren
EP1683811A3 (de) Zusammensetzungen und Methoden zur Behandlung von Tumoren
CA2329137A1 (en) Novel tumor antigen useful in diagnosis and therapy of prostrate and colon cancer
JP2004500895A5 (de)
EP1642907A3 (de) Zusammensetzung und Verfahren zur Diagnose von Tumoren
Ke et al. Elevated expression of calcium‐binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells
ATE287952T1 (de) Humanes thymosin beta 15 gen,protein und dessen verwendungen
Ueyama et al. Structure and expression of rat and mouse mRNAs for Zn-α2-glycoprotein
EP1373499B1 (de) Hin-1, ein tumorsuppressor-gen
Meria et al. Tumour-associated trypsin inhibitor and renal cell carcinoma
CA2347085A1 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
WO1996029402A1 (en) Tumor marker protein for cancer risk assessment
WO1998042830A3 (en) Noey2 gene compositions and methods of use
Ogawa et al. Pancreatic secretory trypsin inhibitor in cancer
ES2295084T3 (es) Un acido nucleico regulado positivamente en celulas cancerosas humanas, una proteina codificada de este modo y un procedimiento para el diagnostico del tumor.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0922223

Country of ref document: EP

REN Ceased due to non-payment of the annual fee